Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by TechnicalBuyon Sep 15, 2012 9:29am

491 Views

Post# 20366762

Good article on recent VEGF trials by Eyelea

Good explanation of VEGF therapy trials vs laser and steroids.

Notice that Eyelea is dosed monthly to start with and then every 2 months thereafter. This is a huge advantage over the current Lucentis therapy which is injected monthly. ICO's 007 would be a major disruptor with a therapy cycle between 4 and 6 months.

https://www.revophth.com/content/c/35993/

TB
technicalbuy.com

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”